Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and market introduction of orally administered enzyme therapies. Operating within the United States, the firm is dedicated to addressing debilitating metabolic and renal conditions, particularly those that are rare and severe. Its primary therapeutic candidate, ALLN-346, is an innovative enzyme designed to break down urate. This treatment is specifically aimed at individuals experiencing hyperuricemia and gout, especially when these conditions coexist with advanced chronic kidney disease. Established in 2011, Allena Pharmaceuticals maintains its corporate headquarters in Newton, Massachusetts.


Net sales
Gross margin
Net income